12:00 AM
 | 
Jan 17, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Peramivir: Phase III amended

BioCryst said it is seeking permission and additional funding from HHS to expand the ongoing, double-blind, placebo-controlled, international Phase III BCX1812-301 trial of peramivir, which the company said could increase the likelihood of a favorable clinical outcome. BioCryst, which is developing peramivir under a contract with HHS, asked the agency for undisclosed additional...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >